Bausch Health Companies Inc.
Close on Oct 19, 2026
- Market cap
- $2.39B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 29, 2026 | After market close | $2.85B | $0.68 | $1.26 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 29, 2026 | After market close | $2.52B | $-3.82 | $0.78 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 18, 2026 | After market close | $2.80B | $-0.30 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | After market close | $2.68B | $0.48 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 30, 2025 | After market close | $2.53B | $0.40 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 30, 2025 | After market close | $2.26B | $-0.16 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 19, 2025 | After market close | $2.56B | $0.25 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | After market close | $2.51B | $-0.23 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 29, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDA 1 (in Billions)non-GAAP | full-year 2026 | $4.05B to $4.18B | Raised |
| Adjusted EBITDA 1 (in Billions) BHC (excl. B+L)non-GAAP | full-year 2026 | $3.03B to $3.10B | Lowered |
| Adj. EBITDA 1 growth vs. Prior Yearnon-GAAP | full-year 2026 | 8% to 11% growth | Raised |
| Adjusted EBITDA 1 (in Billions) B+Lnon-GAAP | full-year 2026 | $1.03B to $1.08B | Lowered |
| Adjusted Cash Flows from Operations 1 (in Billions)non-GAAP | full-year 2026 | $1.40B to $1.48B | New |
| Revenues (in Billions) BHC (excl. B+L)GAAP | full-year 2026 | $5.35B to $5.50B | Lowered |
| Revenue growth vs. Prior Yearnon-GAAP | full-year 2026 | 4% to 6% growth | Raised |
| Revenues (in Billions)GAAP | full-year 2026 | $10.79B to $11.04B | Raised |
| Revenues (in Billions) B+LGAAP | full-year 2026 | $5.44B to $5.54B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Bausch Health Companies filed with the SEC
BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE
Results of operations · EX-99.1 to Form 8-K
Michael Goettler Resigns from Bausch Health’s Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS
Results of operations · EX-99.1 to Form 8-K
BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
Results of operations · EX-99.1 to Form 8-K
Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
Regulation FD disclosure · EX-99.1 to Form 8-K
Bausch + Lomb Completes Refinancing of Outstanding
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Bausch Health Announces Final Results and Expiration of Exchange Offers
Other events · EX-99.1 to Form 8-K
Bausch + Lomb Announces Refinancing of Outstanding
Other events · EX-99.1 to Form 8-K
Bausch Health Announces Early Exchange Offer Results for Exchange Offers
Other events · EX-99.1 to Form 8-K
Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes
Other events · EX-99.1 to Form 8-K
BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2025 RESULTS
Results of operations · EX-99.1 to Form 8-K
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
Agreement terminated · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2025 RESULTS
Results of operations · EX-99.1 to Form 8-K
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing
Other events · EX-99.1 to Form 8-K
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Bausch Health Appoints New Chief Accounting Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Bausch + Lomb Announces Closing of Upsized 675 Million Senior Secured Notes Offering and Partial
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Bausch + Lomb Announces Pricing of
Other events · EX-99.1 to Form 8-K
Bausch + Lomb Announces Launch of Senior Secured
Other events · EX-99.1 to Form 8-K
BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2025 RESULTS
Results of operations · EX-99.1 to Form 8-K
Bausch Health Announces Adoption of Shareholder Rights Plan
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes
Other events · EX-99.1 to Form 8-K
Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
Other events · EX-99.1 to Form 8-K
Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities
Other events · EX-99.2 to Form 8-K
BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2024 RESULTS
Results of operations · EX-99.1 to Form 8-K
BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2024 RESULTS
Results of operations · EX-99.1 to Form 8-K
BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2024 RESULTS
Results of operations · EX-99.1 to Form 8-K
Health Welcomes Two New Members to the Executive Leadership Team
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2024 RESULTS
Results of operations · EX-99.1 to Form 8-K
BAUSCH HEALTH ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2023 RESULTS
Results of operations · EX-99.1 to Form 8-K
Bausch Health Announces Board Refreshment
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BAUSCH HEALTH ANNOUNCES THIRD-QUARTER 2023 RESULTS
Results of operations · EX-99.1 to Form 8-K
BAUSCH HEALTH ANNOUNCES CFO TRANSITION PLAN
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Bausch Healths Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA ®
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
To Management of Novartis Pharma AG
Regulation FD disclosure · EX-99.1 to Form 8-K
For the six months ended June 30, 2023 and June 30, 2022
Regulation FD disclosure · EX-99.2 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Regulation FD disclosure · EX-99.3 to Form 8-K
BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2023 RESULTS, OTHER KEY UPDATES FROM THE QUARTER, AND RAISES FULL-YEAR 2023 REVENUE OUTLOOK
Results of operations · EX-99.1 to Form 8-K
Bausch Health Enters Into $600 Million Financing Facility With KKR
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA ®
Other events · EX-99.1 to Form 8-K